In a major Phase 3 clinical trial, lecanemab showed it could slow the decline in memory and thinking ability by 27% overall ...
An experimental treatment appears to delay Alzheimer’s symptoms in some people genetically destined to get the disease in ...
An experimental treatment appears to delay Alzheimer’s symptoms in some people genetically destined to get the disease in ...
CervoMed's stock soars 400% on promising dementia drug data. See more on insights, potential concerns, and what it means for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results